The US Patent No. 7,428,554 covers a method for determining matching patterns within gene expression data stored in a database comprising of biological data. This robust methodology helps in retrieving clinically relevant and biologically significant patterns by making optimal use of information imbibed in the biological data which includes biological samples, related information on diseases, medications, tissues and other sample parameters present in the database.
The US Patent No. 7426441 covers the elucidation of global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention also includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.
Ms. Anu Acharya, CEO, Ocimum Biosolutions says, "The granting of these patents reflects our continued focus on innovation and commitment to strengthen our intellectual property portfolio. Such cutting-edge research and techniques contribute immensely to our global reputation as a preferred partner for genomic solutions and services with global biotech, pharmaceutical companies and research organizations."
ocimumbio
The researchers also found that in mice without Gpr41, the intestines passed food more quickly. They hypothesized that one action of Gpr41 is to slow down the motion that propels food forward, so that more nutrients can be absorbed. Thus, if the receptor cannot be activated, food is expelled more quickly, and the animal gets less energy from it.
Because mice totally lacking Gpr41 were still healthy and had intestinal function, the receptor may be a likely target for drugs that can slow, but not stop, energy intake, Dr. Yanagisawa said.
Other UT Southwestern researchers involved in the study were co-lead author and graduate student Abdullah Shaito; Dr. Toshiyuki Motoike, assistant professor of molecular genetics; research specialist Clay Willams; and Dr. Robert Hammer, professor of biochemistry. Researchers from Washington University School of Medicine, the Japan Science and Technology Agency and Howard Hughes Medical Institute in Chevy Chase, Md., also participated.
The study was funded by the National Science Foundation, the National Institutes of Health, the W.M. Keck Foundation, the Japan Science and Technology Agency and HHMI.
utsouthwestern/